[{"id":"23608ea2-57cb-4ec4-b52e-66c473bed965","acronym":"","url":"https://clinicaltrials.gov/study/NCT04064359","created_at":"2023-08-10T18:54:54.967Z","updated_at":"2024-07-02T16:35:20.460Z","phase":"Phase 1","brief_title":"Safety and Preliminary Efficacy of OBT076 in Recurrent/Metastatic CD205+ Solid Tumors","source_id_and_acronym":"NCT04064359","lead_sponsor":"Oxford BioTherapeutics Ltd","biomarkers":" LY75","pipe":" | ","alterations":" CD20 positive","tags":["LY75"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e OBT076"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 07/25/2019","start_date":" 07/25/2019","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2024-02-07"},{"id":"98a4f025-5ee8-4f15-ae0b-6980e94aaeb1","acronym":"","url":"https://clinicaltrials.gov/study/NCT04238637","created_at":"2023-11-19T10:15:04.491Z","updated_at":"2025-02-25T15:09:02.238Z","phase":"Phase 2","brief_title":"Immunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC)","source_id_and_acronym":"NCT04238637","lead_sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","biomarkers":" CD8 • PD-1 • CXCL10 • PD-L2 • CXCL9 • CXCL13 • CD68 • FOXP3 • MMP9 • LY75","pipe":" | ","alterations":" PD-L1 expression","tags":["CD8 • PD-1 • CXCL10 • PD-L2 • CXCL9 • CXCL13 • CD68 • FOXP3 • MMP9 • LY75"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 11/01/2019","start_date":" 11/01/2019","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-11-18"},{"id":"7e21b1c1-21f0-4b37-a171-fa51196f862e","acronym":"IMMUNIB","url":"https://clinicaltrials.gov/study/NCT03841201","created_at":"2021-01-18T18:57:47.456Z","updated_at":"2025-02-25T13:35:14.380Z","phase":"Phase 2","brief_title":"Immunotherapy With Nivolumab in Combination With Lenvatinib for Advanced Stage Hepatocellular Carcinoma","source_id_and_acronym":"NCT03841201 - IMMUNIB","lead_sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","biomarkers":" CD8 • PD-1 • CXCL10 • PD-L2 • CXCL9 • CXCL13 • CD68 • FOXP3 • MMP9 • LY75","pipe":"","alterations":" ","tags":["CD8 • PD-1 • CXCL10 • PD-L2 • CXCL9 • CXCL13 • CD68 • FOXP3 • MMP9 • LY75"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Lenvima (lenvatinib)"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 06/12/2019","start_date":" 06/12/2019","primary_txt":" Primary completion: 10/27/2022","primary_completion_date":" 10/27/2022","study_txt":" Completion: 05/02/2023","study_completion_date":" 05/02/2023","last_update_posted":"2023-05-12"}]